Clinical trial
Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
NCT03268057 is registered in ClinicalTrials.gov with Vaccinex Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
- Lead sponsor
- Vaccinex Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 5, 2017
- Completion date
- September 10, 2020
- Enrollment
- 62 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.